id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-2512-0009,FDA,FDA-2022-D-2512,Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin; International Council for Harmonisation; Guidance for Industry; Availability,Notice,Notice of Availability,2024-01-11T05:00:00Z,2024,1,2024-01-11T05:00:00Z,,2024-01-11T15:28:46Z,2024-00407,0,0,0900006486392262
FDA-2022-D-2512-0010,FDA,FDA-2022-D-2512,Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin; Guidance for Industry - Final Guidance,Other,Guidance,2024-01-11T00:00:00Z,2024,1,2024-01-11T00:00:00Z,,2025-05-06T01:33:49Z,,1,0,0900006486392991
FDA-2022-D-2512-0001,FDA,FDA-2022-D-2512,Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin; International Council for Harmonisation; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-11-14T05:00:00Z,2022,11,2022-11-14T05:00:00Z,,2022-11-14T16:04:58Z,2022-24685,0,0,09000064854aab74
FDA-2022-D-2512-0002,FDA,FDA-2022-D-2512,Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin - Draft Guidance for Industry,Other,Guidance,2022-11-14T05:00:00Z,2022,11,2022-11-14T05:00:00Z,2023-01-14T04:59:59Z,2024-01-11T15:31:56Z,,0,0,09000064854ab6f7